Baker McKenzie Baker McKenzie
How Can We Help?
Oren Livne

Oren Livne

Partner
Baker & McKenzie LLP

Biography

Oren Livne is a partner in the Transactions Practice Group and the Life Sciences Industry Group. Before beginning his legal career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Practice Focus

Oren Livne counsels clients from startups to multinationals on a variety of corporate and transactional matters globally, including complex license and collaboration agreements, joint ventures, spin outs, commercial contracts, mergers and acquisitions, and other intellectual property focused transactions. His clients include pharmaceutical, biotech, medical device, consumer product, and technology companies as well as private equity firms.

Representative Legal Matters

  • Astellas in its license agreement with 4D Molecular Therapeutics for the use of 4D's proprietary R100 vector for rare ophthalmic targets, including USD 20 million upfront and potential future option fees and milestones of up to USD 942.5 million.

  • Astellas in its strategic collaboration and option agreement with Cullgen to advance innovative targeted protein degraders, with compensation potentially exceeding USD 1.9 billion if Astellas exercises all of its license options and all milestones for all programs are achieved.

  • L'Oréal in its strategic partnership with Debut to develop a wide variety of novel ingredients and beauty and personal care products using Debut's proprietary cell-free and biotechnology model.

  • L'Oréal in its collaboration with Verily to incorporate Verily's stabilization technology into L'Oréal's smart makeup applicator for users with limited hand and arm mobility.

  • Merck Sharp & Dohme in its collaboration and license agreement with PeptiDream Inc. for the discovery and development of novel peptide drug candidates, including the potential for up to USD 2.1 billion in regulatory, development and commercial milestones.

  • Vividion Therapeutics (a wholly owned and independently operated subsidiary of Bayer AG) in its strategic collaboration with Tavros Therapeutics to discover and enhance targeted oncology programs, including an upfront of USD 17.5 million, up to USD 430.5 million in milestone payments for four initial programs, and, if Vividion exercises its opt-in for up to five more targets, up to USD 482 million in additional payments.

  • Bristol Myers Squibb in its research collaboration with SyntheX to discover and develop targeted protein degradation therapeutics, under which SyntheX will receive an upfront and is eligible for up to USD 550 million in performance-based milestone payments, as well as royalties on global net sales.

  • Astellas in its worldwide strategic collaboration with Sutro Biopharma to advance novel immunostimulatory antibody-drug conjugates (iADCs) under which Sutro will receive an upfront cash payment of USD 90 million and may be eligible to receive up to USD 422.5 million in milestones for each product candidate plus tiered royalties.

  • Galapagos in its acquisition of Cellpoint (including its decentralized point-of-care manufacturing model for CAR-T therapy) for an upfront amount of EUR 125 million, with milestone payments up to EUR 100 million.

  • Bristol Myers Squibb in its strategic collaboration with Amphista Therapeutics for discovery and development of targeted protein degradation therapeutics, including an upfront payment of USD 30 million, the potential for up to USD 1.25 billion in milestone and other payments, as well as royalties on global net sales of product.

  • Abbott in its partnership with CamDiab and Ypsomed for a new automated insulin delivery system for people living with diabetes.

Professional Honors

  • Shortlisted for Licensing & Collaboration Attorney of the Year, LMG Life Sciences, 2023
  • Leading Life Sciences Lawyer, Licensing & Collaboration, LMG Life Sciences, 2021/22, 2022/23
  • Rising Star, Super Lawyers New Jersey, 2020-2022
  • Shortlisted for Innovative Lawyers Award Asia-Pacific, Practice of Law - Healthcare, to Baker McKenzie Healthcare & Life Sciences Group on COVID-19 Response, FT 2021 
  • IFLR Europe M&A Deal of the Year 2020, European Lifestars Deal of the Year 2019 (> GBP 500 million), and Best M&A Award Large-Cap Corporate Deal 2019 (Belgium) for the Galapagos - Gilead collaboration 
  • Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence, 2020
  • Notable Practitioner, IFLR 1000, 2020
  • Rising Star, Healthcare: Life Sciences, The Legal 500 United States, 2019
  • Certified Licensing Professional, 2008-2023

Professional Associations and Memberships

  • New York State Bar Association
  • New Jersey State Bar Association
  • Licensing Executives Society

Admissions

  • New York~United States
  • New Jersey~United States
  • U.S. Patent and Trademark Office~United States

Education

  • New York University (MBA, with distinction) (2012)
  • New York University School of Law (JD) (2012)
  • Rutgers University (BS Chemical Engineering, with Highest Honors) (1996)

Languages

  • English

Publications and Presentations


Baker & McKenzie LLP is a Limited Liability Partnership organized under the laws of the State of Illinois (USA) and is a member of Baker & McKenzie International, a Verein organized under the laws of Switzerland.